Published in J Thromb Thrombolysis on January 01, 2014
Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis (2015) 0.78
Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea. J Clin Neurol (2015) 0.77
The changing characteristics of atrial fibrillation patients treated with warfarin. J Thromb Thrombolysis (2015) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78
Instruments for evaluating education in evidence-based practice: a systematic review. JAMA (2006) 4.50
Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA (2002) 4.36
Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation (2012) 3.74
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Cardiol (2005) 3.01
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol (2003) 2.99
Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation (2004) 2.90
Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2007) 2.88
A campaign to improve the timeliness of primary percutaneous coronary intervention: Door-to-Balloon: An Alliance for Quality. JACC Cardiovasc Interv (2008) 2.69
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med (2004) 2.53
Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation (2007) 2.31
Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med (2003) 2.22
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20
Evidence-based risk communication: a systematic review. Ann Intern Med (2014) 2.14
Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg (2012) 2.12
Correlates of delayed recognition and treatment of acute type A aortic dissection: the International Registry of Acute Aortic Dissection (IRAD). Circulation (2011) 1.97
Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med (2005) 1.92
2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol (2009) 1.86
Impact of duty hours restrictions on quality of care and clinical outcomes. Am J Med (2007) 1.81
Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation (2004) 1.77
The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation (2012) 1.75
Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary syndrome. Arch Intern Med (2005) 1.68
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol (2008) 1.62
National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J Am Coll Cardiol (2009) 1.57
Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView). Am J Respir Crit Care Med (2011) 1.51
Descending aortic diameter of 5.5 cm or greater is not an accurate predictor of acute type B aortic dissection. J Thorac Cardiovasc Surg (2011) 1.49
Perioperative practice: time to throttle back. Ann Intern Med (2009) 1.46
Symptoms of men and women presenting with acute coronary syndromes. Am J Cardiol (2006) 1.46
Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol (2002) 1.45
Congestive heart failure and QRS duration: establishing prognosis study. Chest (2002) 1.28
Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med (2011) 1.24
Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J (2004) 1.19
The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality improvement initiative in percutaneous coronary interventions. J Interv Cardiol (2002) 1.16
The University of Michigan Honest Broker: a Web-based service for clinical and translational research and practice. J Am Med Inform Assoc (2009) 1.11
Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). Thromb Haemost (2014) 1.07
Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thromb J (2008) 1.03
Risk Factors in first presentation acute coronary syndromes (ACS): how do we move from population to individualized risk prediction? Angiology (2009) 1.02
Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother (2005) 1.02
Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord (2005) 1.02
Stroke and outcomes in patients with acute type A aortic dissection. Circulation (2013) 1.01
The IRAD classification system for characterizing survival after aortic dissection. Am J Med (2013) 1.00
Medication performance measures and mortality following acute coronary syndromes. Am J Med (2005) 0.99
Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS One (2009) 0.99
2009 ACCF/AHA focused update on perioperative beta blockade: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation (2009) 0.98
Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol (2003) 0.98
Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol (2011) 0.98
Retroperitoneal hematoma after percutaneous coronary intervention: prevalence, risk factors, management, outcomes, and predictors of mortality: a report from the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry. JACC Cardiovasc Interv (2010) 0.97
Potential drug-drug interactions in the outpatient setting. Med Care (2006) 0.96
Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest Heart Fail (2005) 0.96
Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma. N Engl J Med (2007) 0.94
Comparison of patients with acute coronary syndrome with and without systemic hypertension. Am J Cardiol (2003) 0.93
Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol (2007) 0.93
Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol (2007) 0.91
Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol (2009) 0.90
Health status and behavior among middle-school children in a midwest community: what are the underpinnings of childhood obesity? Am Heart J (2010) 0.89
Gender differences in physiologic markers and health behaviors associated with childhood obesity. Pediatrics (2013) 0.89
Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia. J Am Coll Cardiol (2013) 0.89
Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after discharge. Pharmacotherapy (2011) 0.88
Dual antiplatelet agent failure: a new syndrome or clinical nonentity? Am Heart J (2007) 0.88
Understanding childhood obesity in America: linkages between household income, community resources, and children's behaviors. Am Heart J (2012) 0.87
Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Am Heart J (2005) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
A middle school intervention to improve health behaviors and reduce cardiac risk factors. Am J Med (2013) 0.85
Academic detailing to improve laboratory testing among outpatient medication users. Med Care (2007) 0.85
A quality guarantee in acute coronary syndromes: the American College of Cardiology's Guidelines Applied in Practice program taken real-time. Am Heart J (2007) 0.85
Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein<or=80 mg/dl. Am J Cardiol (2005) 0.85
Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol (2007) 0.85
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol (2008) 0.84
The role of age in complicated acute type B aortic dissection. Ann Thorac Surg (2013) 0.83
National trends in venous disease. J Vasc Surg (2010) 0.83
Transcriptomic profiling-based mutant screen reveals three new transcription factors mediating menadione resistance in Neurospora crassa. Fungal Biol (2013) 0.83